Literature DB >> 29979668

Patent mining and landscaping of emerging recombinant factor VIII through network analysis.

Cristiano Gonçalves Pereira1, Virgínia Picanco-Castro2, Dimas Tadeu Covas2, Geciane Silveira Porto1,3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29979668     DOI： 10.1038/nbt.4178

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  13 in total

1.  The emerging patent landscape of CRISPR-Cas gene editing technology.

Authors:  Knut J Egelie; Gregory D Graff; Sabina P Strand; Berit Johansen
Journal:  Nat Biotechnol       Date:  2016-10-11       Impact factor: 54.908

2.  Extended half-life clotting factor concentrates: results from published clinical trials.

Authors:  G Young; J N Mahlangu
Journal:  Haemophilia       Date:  2016-07       Impact factor: 4.287

3.  The global intellectual property landscape of induced pluripotent stem cell technologies.

Authors:  MacKenna Roberts; Ivan B Wall; Ian Bingham; Dominic Icely; Brock Reeve; Kim Bure; Anna French; David A Brindley
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

4.  Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.

Authors:  Jennifer A Dumont; Tongyao Liu; Susan C Low; Xin Zhang; George Kamphaus; Paul Sakorafas; Cara Fraley; Douglas Drager; Thomas Reidy; Justin McCue; Helen W G Franck; Elizabeth P Merricks; Timothy C Nichols; Alan J Bitonti; Glenn F Pierce; Haiyan Jiang
Journal:  Blood       Date:  2012-01-13       Impact factor: 22.113

5.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

Authors:  Jan Astermark; Sharyne M Donfield; Donna M DiMichele; Alessandro Gringeri; Steven A Gilbert; Jennifer Waters; Erik Berntorp
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

6.  Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.

Authors:  Sabine B Zollner; Elmar Raquet; Jochen Müller-Cohrs; Hubert J Metzner; Thomas Weimer; Ingo Pragst; Gerhard Dickneite; Stefan Schulte
Journal:  Thromb Res       Date:  2013-07-05       Impact factor: 3.944

7.  A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.

Authors:  Naoki Uchida; Takehiko Sambe; Koichiro Yoneyama; Naoki Fukazawa; Takehiko Kawanishi; Shinichi Kobayashi; Midori Shima
Journal:  Blood       Date:  2015-12-01       Impact factor: 22.113

8.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.

Authors:  Barbara A Konkle; Oleksandra Stasyshyn; Pratima Chowdary; David H Bevan; Tim Mant; Midori Shima; Werner Engl; Jacqueline Dyck-Jones; Monika Fuerlinger; Lisa Patrone; Bruce Ewenstein; Brigitt Abbuehl
Journal:  Blood       Date:  2015-07-08       Impact factor: 22.113

9.  Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.

Authors:  A Tiede; B Brand; R Fischer; K Kavakli; S R Lentz; T Matsushita; C Rea; K Knobe; D Viuff
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

10.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

Authors:  Johnny Mahlangu; Jerry S Powell; Margaret V Ragni; Pratima Chowdary; Neil C Josephson; Ingrid Pabinger; Hideji Hanabusa; Naresh Gupta; Roshni Kulkarni; Patrick Fogarty; David Perry; Amy Shapiro; K John Pasi; Shashikant Apte; Ivan Nestorov; Haiyan Jiang; Shuanglian Li; Srividya Neelakantan; Lynda M Cristiano; Jaya Goyal; Jurg M Sommer; Jennifer A Dumont; Nigel Dodd; Karen Nugent; Gloria Vigliani; Alvin Luk; Aoife Brennan; Glenn F Pierce
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113
View more
  1 in total

1.  Emerging CAR T cell therapies: clinical landscape and patent technological routes.

Authors:  Virgínia Picanco-Castro; Cristiano Gonçalves Pereira; Kamilla Swiech; Kelen Cristina Ribeiro Malmegrim; Dimas Tadeu Covas; Geciane Silveira Porto
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.